Cell>Point News & Publications

Diagnostic Imaging

Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC- Amifostine as a potentially effective theranostic technology for COVID-19

Posted on: March 24th, 2020

CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program to clinically develop 99mTc-EC-Amifostine and 177Lu-EC-Amifostine to assess, treat and follow-up with confirmatory imaging for people who contract COVID-19. For example, EC-Amifostine is metabolized by alkaline phosphatase (ALP) to a thiol analog, followed by scavenging free-radicals and…

Read More

Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia Imaging Platform

Posted on: January 21st, 2020

CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia®, that it will be moving forward with these two intra-nuclear therapeutics expanding…

Read More

Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the new one-vial Oncardia

Posted on: January 21st, 2020

CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company’s new one-vial Oncardia® (ethylenedicysteine-glucosamine) kits.  The 60 patient trial study is being conducted in the U.S. Today, slightly greater than 6 million…

Read More

CellPoint, L.L.C. announced today that it has entered into automated production agreement with KP Pharmaceutical Technologies for lead molecular imaging agent Oncardia®

Posted on: September 19th, 2018

CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with KP Pharmaceutical Technology, Inc. to produce 1mg vials of its lead agent Oncardia®(ethylenedicysteine-glucosamine).   CellPoint is currently completing Phase 2b and 3 nuclear imaging trials with 99mTc-Oncardia® in both cardiology and oncology imaging. The new formulation will simplify the…

Read More

Noninferiority of 99mTc Ethylenedicystein Glucosamine (Oncarida) as a Alternative Analogue to 18F Flurodeoxyglucose in the Detection and Staging of Non Small Cell Lung Cancer

Posted on: March 19th, 2018

Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://cellpointweb.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf

Read More

Targeting the Hexosamine Biosynthetic Pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma

Posted on: October 3rd, 2016

Oncotarget, Advance Publications 2016 https://cellpointweb.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf

Read More

Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology

Posted on: August 25th, 2016

CENTENNIAL, Colo., August 24, 2016  – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic stress disorder (“PTSD”),…

Read More

Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia® for Cancer and Heart Disease Diagnostic Imaging

Posted on: June 17th, 2016

CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the U.S. and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia® (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for…

Read More

Cell>Point Announces Postive Results from 99mTc-Oncardia® (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cancer.

Posted on: February 26th, 2015

CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a  physician initiated IND study at the University of Chicago Medical Center. The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia®…

Read More

Patched Targeted Peptides for Imaging and Treatment of Hedgehog Positive Breast Tumors

Posted on: September 21st, 2014

Published: September 2014, Bio Medical Research International https://cellpointweb.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf

Read More